Baxter International Inc. BAX
Healthcare · Medical Instruments & Supplies · United States · S&P 500
Based on the available data, Baxter International Inc. gets an algorithmic score of 57/100. It trades at 23.48 $, with a bullish technical trend (RSI 40.0) and 43.0% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low valuation (P/E 11.5).
- Meaningful dividend (17.00%).
Weaknesses
- Low ROE (-14.4%).
- Thin net margin (-9.3%): vulnerable to costs.
Fundamentals
| Forward P/E | 11.53 |
| PEG | 36.68 |
| P/B | 1.96 |
| EV/EBITDA | 10.42 |
| P/S | 1.06 |
| ROE % | -14.37 |
| ROA % | 2.85 |
| Gross margin % | 34.10 |
| Operating margin % | 14.43 |
| Net margin % | -9.27 |
| Revenue growth % (y/y) | 5.30 |
| Earnings growth % (y/y) | 36.80 |
| Revenue CAGR % | 3.79 |
| Debt/Equity % | 156.45 |
| Current ratio | 1.95 |
| FCF yield % | 2.66 |
| Dividend yield % | 17.00 |
| Payout % | 307.69 |
Returns
| 1 month | -10.1 % |
| 3 months | +10.2 % |
| 6 months | +48.7 % |
| YTD | +20.6 % |
| 1 year | +7.0 % |
| 3 years | -34.1 % |
| 5 years | -68.4 % |
Risk
| 1-year volatility | 43.0 % |
| Beta | 0.82 |
| 5-year max drawdown | -80.6 % |
| Sharpe 1A | 0.28 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.